Drug intelligence / Profile preview

casin

Development stage: Preclinical
Modality: Small Molecules
Administration: In Vitro, In Vivo (research Use; Not Approved For Clinical Administration)

Overview

CASIN is a small molecule inhibitor that selectively targets Cdc42, a Rho GTPase protein involved in cell cycle regulation, migration, morphology, and endocytosis. It acts by binding to Cdc42-GDP and inhibiting the dissociation of GDP, reducing Cdc42 activity. CASIN has demonstrated the ability to rejuvenate aged hematopoietic stem cells (HSCs) in vitro and in vivo by restoring cell polarity and histone H4K16 acetylation, and improving HSC repopulation ability. It is currently a research tool in preclinical development and has not been approved for human use.[1][2][3][4][5][6][7]

Other names: CASIN2-[(6-Phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino]ethanol2-((6-phenyl-2,3,4,9-tetrahydro-1H-carbazol-1-yl)amino)ethanol

Targets

CDC42 (Cell division control protein 42 homolog)

Beyond the preview

Go deeper on casin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on casin.

Explore the full profile